Doorgaan naar hoofdnavigatie Doorgaan naar zoeken Ga verder naar hoofdinhoud

Phages and phage-borne enzymes as new antibacterial agents

  • ESGNTA – ESCMID study group for non-traditional antibacterials
    • Balgrist University Hospital
    • European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Non-traditional Antibacterial Therapy (ESGNTA)
    • University of Wroclaw
    • Hospices Civils de Lyon
    • Université Claude Bernard Lyon 1
    • Hadassah University Medical Center
    • Faculty of Medicine

    Onderzoeksoutput: Bijdrage aan een tijdschriftArtikel recenserenpeer review

    24 Citaten (Scopus)

    Samenvatting

    Background: Persistent and resistant infections caused by bacteria are increasing in numbers and pose a treatment challenge to the medical community and public health. However, solutions with new agents that will enable effective treatment are lacking or delayed by complex development and authorizations. Bacteriophages are known as a possible solution for invasive infections for decades but were seldom used in the Western world. Objectives: To provide an overview of the current status and emerging use of bacteriophage therapy and phage-based products, as well as touch on the socioeconomic and regulatory issues surrounding their development. Sources: Peer-reviewed articles and authors' first-hand experience. Content: Although phage therapy is making a comeback since its early discovery, there are many hurdles to its current use. The lack of appropriate standardized bacterial susceptibility testing; lack of a simple business model and authorization for the need of many phages to treat a single species infection; and the lack of knowledge on predictable outcome measures are just a few examples. In this review, we explore the possible routes for phage use, either based on local specialty centres or by industry; the current status of phage therapy, which is mainly based on single-centre or single-bacterial cohorts, and emerging clinical trials; local country-level frameworks for phage utilization even without full authorization; and the use of phage-derived products as alternatives to antibiotics. We also explore what may be the current indications based on the possible availability of phages. Implications: Although phages are emerging as a potential treatment for non-resolving and life-threatening infections, the models for their use and production still need to be defined by the medical community, regulatory bodies, and industry. Bacteriophages may have a great potential for infection treatment but many aspects still need to be defined before their routine use in the clinic.

    Originele taal-2Engels
    Pagina's (van-tot)910-921
    Aantal pagina's12
    TijdschriftClinical Microbiology and Infection
    Volume31
    Nummer van het tijdschrift6
    DOI's
    StatusGepubliceerd - jun 2025

    Vingerafdruk

    Duik in de onderzoeksthema's van 'Phages and phage-borne enzymes as new antibacterial agents'. Samen vormen ze een unieke vingerafdruk.

    Citeer dit